Tenax Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 60   

Articles published

TENX 2.33 -0.05 (-2.10%)
price chart
Latest Analysts Reports On Tenax Therapeutics, Inc. (TENX)
Recently stock market analysts have updated their consensus ratings on shares of Tenax Therapeutics, Inc. (TENX). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 ...
Tenax Therapeutics, Inc. (NASDAQ:TENX) Analyst Ratings and Target Update  Uptick Analyst
Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS
Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provided an update for its ongoing Phase 3 LEVO-CTS trial for lead candidate ...
Oxygen Biotherapeutics Announces Name Change to Tenax Therapeutics (NASDAQ: TENX)
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the Company ...
Related articles »  
Tenax Therapeutics Highlights Completion of Enrollment for LeoPARDS Trial by ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today highlighted that Imperial College ...
Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provided a detailed clinical ...
Tenax Therapeutics Inc (NASDAQ:TENX) director Ronald Blanck, Buys $6080 in Stock
After the disclosing of a document filled with U.S. Security & Exchange Commission; a new insider trading deal became apparent.
Tenax Therapeutics: Evaluating Levosimendan In Septic Shock
Tenax Therapeutics, Inc. (NASDAQ:TENX) is a development-stage specialty pharmaceutical company focused on the identification, development, and commercialization of products for critical care patients.
Recent Broker Updates On Tenax Therapeutics, Inc. (TENX)
Recently stock market analysts have updated their consensus ratings on shares of Tenax Therapeutics, Inc. (TENX). The latest broker reports which are currently outstanding on Friday 29th January state 1 analyst has a rating of “strong buy”, 2 analysts ...
Tenax Therapeutics Announces First Quarter Fiscal Year 2016 Financial Results
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced financial results for the ...
Tenax Therapeutics' (TENX) CEO John Kelley on Q2 2015 Results - Earnings Call ...
Joining me on the call today is John Kelley, Chief Executive Officer of Tenax Therapeutics who will discuss recent company highlights. Following John, Michael Jebsen, Tenax's Chief Financial Officer will review the company's financial results for the ...
Related articles »